3,940,194 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Norges Bank

Norges Bank acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 3,940,194 shares of the company’s stock, valued at approximately $163,833,000. Norges Bank owned approximately 1.02% of Moderna at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of MRNA. State Street Corp increased its stake in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the last quarter. Amundi boosted its stake in Moderna by 79.8% in the fourth quarter. Amundi now owns 1,206,273 shares of the company’s stock valued at $52,075,000 after buying an additional 535,273 shares in the last quarter. Two Sigma Advisers LP bought a new position in Moderna in the third quarter valued at about $23,825,000. Finally, Douglas Lane & Associates LLC raised its stake in Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after acquiring an additional 298,715 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Berenberg Bank raised their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Morgan Stanley reduced their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Citigroup started coverage on Moderna in a research note on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. Finally, Evercore ISI set a $50.00 price objective on Moderna in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $59.00.

Moderna Stock Down 8.9 %

NASDAQ:MRNA opened at $28.35 on Tuesday. Moderna, Inc. has a twelve month low of $26.80 and a twelve month high of $170.47. The company has a fifty day moving average of $34.60 and a 200-day moving average of $43.84. The firm has a market capitalization of $10.96 billion, a P/E ratio of -3.05 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.